MRC1 and neoplasm: IHC analysis of mouse homograft tumors revealed a significantly reduced expression of CD206+ (a specific marker of M2-type tumor-associated macrophages) in the PC3-PSM-E-Exos treatment group, while a higher expression of CD206+ was observed in the LNCaP-siPSM-E-Exos treatment group (Fig. 7E).